The continued support we received from LDC has been instrumental in allowing us to maintain growth, champion R&D and realise our global expansion ambitions. We have a number of exciting product developments in the pipeline, and look forward to evolving our offering even further.”Chris Eccles, CEO
Securing overseas expansion
At the heart of the management team’s plans was accelerating global sales of ChargePoint Technology’s innovative AseptiSafe® Bio product, a valve built to deliver increased assurance to customers working with toxic and sensitive substances, by investing in an international sales and marketing drive.
The funding also allowed the team to increase spending on new product development to expand the business into adjacent sectors also requiring containment and sterile-transfer solutions.
In 2017 ChargePoint Technology was recognised for exceptional profit growth in The Sunday Times Profit Track 100, placing 27th on the list. This marked the company’s debut in the league table, which ranks Britain’s privately-owned companies with the fastest-growing profits over three years.
In September 2019, the business announced strong sales growth after a year of new product launches and international success.
It has also secured several new contract wins in Canada, which strengthened its presence further in the North American region and helped to grow its UK headcount by 15 per cent, from 74 to 85 people.
With our support, ChargePoint Technology has a strong platform for future growth and its plans include a pipeline of forthcoming product developments.
With the team’s track record in the sector and its in-depth experience of delivering international growth, we’re confident we have the right people in place to help us take our market-leading technology even further afield.”Chris Eccles, CEO
Deal of the Year
Insider North West Dealmakers